Scarica l'app Stockscreener
31.91
0.06%
0.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$31.89
Aprire:
$32.35
Volume 24 ore:
509.91K
Relative Volume:
0.64
Capitalizzazione di mercato:
$1.82B
Reddito:
$199.89M
Utile/perdita netta:
$52.48M
Rapporto P/E:
37.54
EPS:
0.85
Flusso di cassa netto:
$61.15M
1 W Prestazione:
-1.51%
1M Prestazione:
+4.35%
6M Prestazione:
+88.70%
1 anno Prestazione:
+200.19%
Intervallo 1D:
$31.58
$33.23
Intervallo di 1 settimana:
$30.75
$33.28
Portata 52W:
$5.35
$38.69
Stoke Therapeutics Inc Stock (STOK) Company Profile
Nome
Stoke Therapeutics Inc
Settore
Industria
Telefono
781-430-8200
Indirizzo
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
31.91 | 1.82B | 199.89M | 52.48M | 61.15M | 0.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-05 | Iniziato | Guggenheim | Buy |
| 2026-01-05 | Ripresa | Chardan Capital Markets | Buy |
| 2025-07-18 | Iniziato | Jefferies | Buy |
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-03-26 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-07-25 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Ripresa | Canaccord Genuity | Buy |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-10-24 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Iniziato | Jefferies | Buy |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-11-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Iniziato | UBS | Neutral |
| 2021-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-15 | Ripresa | H.C. Wainwright | Buy |
| 2020-12-11 | Reiterato | Needham | Buy |
| 2020-10-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-09-29 | Iniziato | Needham | Buy |
| 2019-12-18 | Iniziato | Wedbush | Outperform |
| 2019-11-12 | Iniziato | BTIG Research | Buy |
| 2019-10-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-07-15 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Cowen | Outperform |
| 2019-07-15 | Iniziato | Credit Suisse | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
Ideas Watch: What is the earnings history of Stoke Therapeutics IncQuarterly Trade Review & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
US Market Recap: What is the earnings history of Stoke Therapeutics IncAnalyst Upgrade & AI Forecast Swing Trade Picks - baoquankhu1.vn
STOK: Four-year data show durable seizure reduction and cognitive gains, with phase 3 readout expected 2027 - TradingView
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Mo - pharmiweb.com
Stoke Therapeutics announces first patient dosed in Phase 1 study of STK-002 - marketscreener.com
Is Stoke Therapeutics Inc. a cyclical or defensive stockQuarterly Earnings Report & Daily Technical Forecast Reports - mfd.ru
Stoke Therapeutics announced that the dose-escalation phase for the first four cohorts of its research project will continue into 2026 and early 2027. - Bitget
Stoke Therapeutics Announces First Patient Dosed In Phase 1 Study Of Stk-002 - TradingView
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA) - Yahoo Finance
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Quarterly Earnings: What is the PEG ratio of Stoke Therapeutics IncJuly 2025 Movers & Fast Gain Stock Trading Tips - baoquankhu1.vn
Guggenheim Upgrades Stoke Therapeutics (NASDAQ:STOK) to "Strong-Buy" - MarketBeat
Why (STOK) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Earnings Recap: How does Stoke Therapeutics Inc score in quality rankingsShare Buyback & Target Return Focused Stock Picks - baoquankhu1.vn
Penserra Capital Management LLC Acquires New Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics stock jumps after Guggenheim initiates with Buy rating By Investing.com - Investing.com South Africa
Stoke Therapeutics stock jumps after Guggenheim initiates with Buy rating - Investing.com
Guggenheim Initiates Coverage on Stoke Therapeutics With Buy Rating, $60 Price Target - marketscreener.com
Guggenheim initiates Stoke Therapeutics stock with Buy rating on Dravet drug - Investing.com Canada
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - pharmiweb.com
Aug Action: Can Stoke Therapeutics Inc navigate macro headwindsEarnings Miss & Growth-Oriented Investment Plans - baoquankhu1.vn
Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Sentiment Watch: Should I hold or sell Stoke Therapeutics Inc nowJuly 2025 Opening Moves & Weekly Breakout Watchlists - baoquankhu1.vn
Breakouts Watch: Does FULT outperform in volatile marketsJuly 2025 Opening Moves & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Commit To Buy Stoke Therapeutics At $20, Earn 20.2% Annualized Using Options - Nasdaq
Stoke Therapeutics, Inc. (STOK) Investor Outlook: A Promising 27.53% Upside Potential In Biotech - DirectorsTalk Interviews
Stoke Therapeutics (NASDAQ:STOK) Trading 6.2% HigherHere's What Happened - MarketBeat
Stoke Therapeutics Expands with New Long-Term Waltham Headquarters - TipRanks
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA - Finviz
Stoke Therapeutics Shares Face Pressure from Strategic Expansion - AD HOC NEWS
Understanding Momentum Shifts in (STOK) - Stock Traders Daily
Should value investors consider Stoke Therapeutics Inc2025 Volatility Report & Low Risk High Win Rate Picks - baoquankhu1.vn
Stoke Therapeutics (STOK) Stock Analysis: Unveiling Growth Potential with a 23.54% Upside - DirectorsTalk Interviews
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
Stoke Therapeutics, Inc. $STOK is Skorpios Trust's Largest Position - MarketBeat
Trial testing breakthrough Dravet drug zorevunersen now nearly full - Dravet Syndrome News
Stoke Therapeutics (STOK) price target increased by 10.42% to 36.46 - MSN
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Avoiding Lag: Real-Time Signals in (STOK) Movement - Stock Traders Daily
Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity (NASDAQ:STOK) - Seeking Alpha
Stoke Therapeutics (STOK) Price Target Increased by 10.42% to 36.46 - Nasdaq
STOK: Phase III for Dravet therapy nears full enrollment, with durable efficacy and regulatory momentum - TradingView — Track All Markets
Stoke Therapeutics stock falls after delayed Phase 3 readout timeline By Investing.com - Investing.com Australia
Stoke Therapeutics (NASDAQ:STOK) Shares Gap DownHere's What Happened - MarketBeat
Stoke Therapeutics stock maintains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Canada
Stoke Therapeutics stock maintains Overweight rating at Cantor Fitzgerald - Investing.com
Phase III update Stokes hope; Dravet game-change Encoded? - BioWorld MedTech
Wedbush Raises Price Target for Stoke Therapeutics (STOK) to $36 - GuruFocus
Stoke Therapeutics Says US FDA Seeks Additional Information for Zorevunersen in Dravet Syndrome; Shares Fall - marketscreener.com
Stoke Therapeutics stock falls after delayed Phase 3 readout timeline - Investing.com
Stoke Therapeutics Inc Azioni (STOK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):